$20 million fundraising initiative will support efforts to improve treatment for lung disease

UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on identifying the causes of and potential treatments for transplant rejection and advanced lung diseases, including chronic obstructive pulmonary disease, emphysema, idiopathic pulmonary fibrosis, sarcoidosis an d interstitial lung disease.Because of the overlap among those conditions, discoveries related to one disease could help lead to advances in understanding and treating the others.“Existing treatments for advanced lung diseases are unimpressive and leave patients with one option — lung transplantation,” said Belperio, who holds the Guitiara Pierpoint Endowed Chair in Interstitial Pulmonary Fibrosis. “Unfortunately, transplantation is not a cure, with only half of lung transplant recipients surviving five years. “Our patients deserve better. We need novel treatments that improve patients’ quality of life and ultimately...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Authors: Montgomery E, Macdonald PS, Jha SR, Newton PJ, Malouf M PMID: 31815560 [PubMed - as supplied by publisher]
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
ConclusionThere is a high prevalence of cognitive impairment identified by neuropsychological tests in older patients with hematological malignancies evaluated for HCT. Identification of an appropriate MoCA cut-off score in this population is important to identify patients who would benefit from further assessment.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Authors: Ye X, Zhou XJ, Zhang H Abstract Autophagy is an important biology process, central to the maintenance of biology process in both physiological and pathological situations. It is regarded as a "double-edged sword"-exerting both protective and/or detrimental effects. These two-way effects are observed in immune cells as well as renal resident cells, including podocytes, mesangial cells, tubular epithelial cells, and endothelial cells of the glomerular capillaries. Mounting evidence suggests that autophagy is implicated in the pathological process of various immune-related renal diseases (IRRDs) as ...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Authors: Zhang X, Tenerelli K, Wu S, Xia X, Yokota S, Sun C, Galvao J, Venugopalan P, Li C, Madaan A, Goldberg JL, Chang KC Abstract BACKGROUND: Glaucoma, the number one cause of irreversible blindness, is characterized by the loss of retinal ganglion cells (RGCs), which do not regenerate in humans or mammals after cell death. Cell transplantation provides an opportunity to restore vision in glaucoma, or other optic neuropathies. Since transplanting primary RGCs from deceased donor tissues may not be feasible, stem cell-derived RGCs could provide a plausible alternative source of donor cells for transplant. OBJ...
Source: Restorative Neurology and Neuroscience - Category: Neurology Tags: Restor Neurol Neurosci Source Type: research
I used this forum a lot in the past. Here is my 2 cents and time to give back. The data listed below represent the info for the calendar year of 2019, and can be different if you look up next year or later. First off, it's difficult to understand &compare what each institution does as essentially no two program will train you the same way. However, certain things are quantifiable such as PCI volume, transplant, ICDs etc. Please find some helpful links to databases below: Transplant: [URL... Cardiology fellowship program reviews. Facts and impressions
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Cardiology Source Type: forums
ConclusionsSteady-state PK parameters of budesonide, glycopyrronium, and formoterol were similar after 7 days’ dosing in the phase I PK study and after 24 weeks in the KRONOS PK sub-study. Systemic exposure to budesonide, glycopyrronium, and formoterol was generally comparable across treatments in the KRONOS PK sub-study, suggesting no meaningful drug–drug or within-formulation PK interactions.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
Researchers from Case Western Reserve University in Ohio found those who lived in areas with high pollution levels were 26 per cent more likely to die within 4.8 years of the operation.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
In only the third documented such procedure, an international team of surgeons met in Belgrade, Serbia, to transplant a testicle from one twin to the other, restoring testosterone.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Chronic Obstructive Pulmonary | Emphysema | Fundraising | Interstitial Lung Disease | Laboratory Medicine | Lung Transplant | Research | Sarcoidosis | Transplant Surgery | Transplants | Universities & Medical Training